Key facts
- This page summarizes Andrew Gengos's Form 3 filing for Immuneering Corp (IMRX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 16 Jul 2026, 16:10.
Andrew Gengos - 16 Jul 2026 Form 3 Insider Report for Immuneering Corp (IMRX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- IMRX
- Reported as of
- 16 Jul 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 16 Jul 2026, 16:10:38 UTC
- Prior SEC filing
- 08 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael D. Bookman, Attorney-in-Fact for Andrew Gengos
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Andrew Gengos filed Form 3 for Immuneering Corp (IMRX) on 16 Jul 2026.
Change
- Previous filing in this sequence was filed on 08 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001563623
Primary reporting owner
Gengos Andrew
- Relationship
- Chief Financial Officer
- Address
- 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
- Signature
- /s/ Michael D. Bookman, Attorney-in-Fact for Andrew Gengos
- Signature date
- 16 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMRX
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 225,000
- Date
- 16 Jul 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.